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Abstract: Over the last decade, extensive studies have been made to understand the role 
played by the mammalian target of rapamycin (mTOR) in cancer. Knowledge in this field 
has been gained from discoveries in basic research as well as from observations made in 
patients treated with allosteric mTOR inhibitors such as rapamycin. Despite promising 
preclinical studies, targeting mTOR in cancer therapy has shown limited clinical benefits 
so far. However, recent findings have revealed the complexity of the functions of mTOR in 
cancer and have helped develop new strategies to improve the anticancer efficacy of 
mTOR inhibitors. In particular, a complex network between mTOR and other signaling 
pathways has been identified that influences the anticancer efficacy of mTOR inhibitors.  
In addition, an emerging role of mTOR in the tumor microenvironment has been 
suggested. In this review, we confront the major findings that have been made in the past, 
both in experimental settings as well as in clinical trials. We further review the strategies 
that have been designed to further improve the efficacy of therapies targeting mTOR. 
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1. Introduction 
Tumor development results from complex processes that enable a tumor to grow and metastasize. 
Several hallmarks have been proposed as necessary for tumor development. They include: Sustaining 
proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming energy 
metabolism and avoiding immune destruction [1]. Interestingly, the mammalian target of rapamycin 
(mTOR) has been shown to play a role in several aspects of these hallmarks and, accordingly, 
represents an important player in the biology of tumors. Indeed, mTOR regulates cell growth, 
proliferation and survival and is at the crossroads of different signaling pathways that are frequently 
mutated in various types of cancer [2]. As a consequence, the resulting over-activation of mTOR leads 
to a sustaining of proliferative signals and resistance to cell death. Furthermore, a function for mTOR 
in cancer invasion and metastasis has also been demonstrated and mTOR plays an emerging role in 
cell metabolism [3]. In addition to the proliferating cancer cells, tumors are also composed of a 
microenvironment that contains distinct cell types, including endothelial cells, innate and adaptive 
immune cells and fibroblasts that influence the growth of a tumor. The role of mTOR in these cells has 
also been partially characterized. In fact, mTOR is an important mediator of tumor angiogenesis and 
the immunosuppressive effects of mTOR inhibitors has been known for decades and is being exploited 
in transplanted patients [4,5]. Hence, mTOR influences tumor growth by playing a global role that is 
not restricted to cancer cell proliferation and survival but that also affects the angiogenic and the 
immunological responses found in the microenvironment of a tumor. 
A first round of clinical trials in cancer patients has been performed, evaluating the anticancer 
efficacy of rapamycin (sirolimus) and rapamycin like drugs (rapalogs) including RAD001 
(everolimus), CCI-779 (temsirolimus) and AP23573 (deferolimus). Overall, rapalogs were less 
successful than expected, generating objective responses in few cancers. Although these clinical trials 
may challenge the relevance of targeting mTOR in cancer therapy, recent findings have demonstrated 
the complex consequences of blocking mTOR in cancer cells and have helped develop new therapeutic 
strategies aimed to improve the anticancer efficacy of mTOR inhibitors. Here, we review the role 
played by mTOR in cancer biology. We further analyze the knowledge that we have obtained from the 
use of mTOR inhibitors in clinical and in basic research. Finally, we enumerate new strategies of 
mTOR-based therapies in oncology. 
2. mTOR Signaling Pathway in Cancer 
mTOR is a 289 kDa protein that belongs to the phosphatidylinositol 3-kinase-related kinase family [6]. 
mTOR exerts its biological functions as being part of two different protein complexes; the mTOR 
complex 1 (mTORC1) and the mTOR complex 2 (mTORC2). mTORC1 is composed of Raptor, 
mTOR, mLST8, Deptor and PRAS40 and is regulated by oxygen levels, amino acids, energy and 
growth factors. Upon activation, mTORC1 participates in translation initiation and protein synthesis by 
phosphorylating at least two well-characterized effectors, S6K1 and 4E-BP1 [3]. In addition, one 
major consequence of mTORC1 inhibition is the downregulation of several mRNA coding for proteins 
implicated in the G1-S phase progression. This results in reduced cell proliferation by inducing a G1 
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arrest and accounts in part for the anti-proliferative properties of mTOR inhibitors [7]. mTORC2 
consists of Rictor, mTOR, mLST8, Protor, Deptor as well as mSin1 and is regulated by growth factors. 
Downstream effectors of mTORC2 are Akt, which regulates cell proliferation and survival, and PKC 
alpha, which controls cytoskeletal organization [8]. mTORC2 also activates SGK1, however the 
functional significance of this activation needs to be further characterized (Figure 1). 
Figure 1. mTOR (the mammalian target of rapamycin ) and its two complexes mTORC1 
and mTORC2. mTOR is part of two functionally distinct complex; mTORC1 and 
mTORC2. mTORC1 is composed of mTOR, PRAS40, Raptor, Deptor and GL and 
regulates among others cell growth and proliferation by phosphorylating 4E-BP1and S6K. 
mTORC2 is composed of Protor, Rictor, Deptor, GL and mSin1 and regulates cell 
survival and proliferation by activating Akt, PKC and SGK. 
 
The molecular mechanisms that regulate the activation of mTORC1 have been extensively studied. 
Among these, the phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway has been identified as a 
major mediator of growth factors-induced mTORC1 activation (Figure 2) [3,6]. Following stimulation 
with growth factors, PI3K is activated and catalyzes the formation of phosphoinositide-3,4,5-tri-
phosphate (PIP3) resulting in the recruitment to the plasma membrane and to the activation of Akt. In 
turn, Akt inactivates TSC2, a large protein that is part of the TSC1-TSC2 complex. Inactivation of the 
TSC1/2 complex leads to the activation of the small GTPase Rheb which stimulates the kinase activity 
of mTORC1 [3]. In addition to its effect on TSC2, Akt also inactivates PRAS40 preventing it from 
blocking mTORC1 activity [9]. In parallel to the PI3K/Akt axis, growth factors also stimulate 
mTORC1 activity through the Mek/Erk signaling pathway [10]. Phosphorylation of TSC2 by Erk or 
phosphorylation of raptor by p90RSK, a downstream effector of Erk, have both been proposed to 
explain the activation of mTORC1 by Erk signaling pathway [11]. 
The molecular mechanisms by which mTORC1 is regulated by stimuli other than growth factors 
have also been partially described [3]. Low energy levels result in decreased AMP/ATP ratio which 
leads to the activation of AMPK. AMPK phosphorylates and activates TSC2 inducing the inhibition of 
mTORC1 [12]. Furthermore, it has also been suggested that AMPK decreases the kinase activity by 
directly phosphorylating raptor, inducing its binding to 14-3-3. Of clinical importance, LKB1 a protein 
mutated in the Peutz-Jeghers syndrome, is an upstream activator of AMPK [13]. Hypoxia also inhibits 
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mTORC1 activity either by reducing ATP levels and thus activating AMPK or by inducing the 
expression of REDD1 that inhibits mTORC1 by stabilizing the TSC1/TSC2 complex [14]. Amino 
acids signaling to mTORC1 involves the recruitment of mTORC1 to lysosomal membranes. In turn, 
mTORC1 associates with Rag GTPases which promotes its interaction with the lysosomal pool of 
Rheb [15,16]. Finally, DNA damage also downregulates mTORC1 activity in a p53-dependent process 
which involves transactivation of negative regulators of mTORC1, such as TSC2 and AMPK [17]. 
In contrast to mTORC1, little is known about the upstream regulators of mTORC2. Recent findings 
suggest that the activation of mTORC2 requires its association with ribosomes and that this association 
requires PI3K activity (Figure 2) [18]. In addition, PIP3, the product of PI3K also directly stimulates 
the activity of mTORC2 in kinase assay [19]. The role of the ribosome has however not been 
characterized in this context. 
Figure 2. Growth factors mediated mTORC1 and mTORC2 activation. The stimulation of 
growth factor receptors by their ligands leads to the activation of PI3K wich catalyzes the 
formation of phosphoinositide-3,4,5-tri-phosphate (PIP3). This triggers the translocation of 
Akt to the membrane where it gets activated by the phosphoinositide-dependent kinase 1 
(PDK1). In addition, the activation of Akt requires the phosphorylation by mTORC2. Once 
activated Akt positively regulates mTORC1 by either inhibiting PRAS40 or TSC2, two 
negative regulators of mTORC1. mTORC2 activation requires its association to the 
ribosomes which is enhanced by PI3K activity. Finally, the lipid phosphatase PTEN acts as 
a negative regulator of this pathway by converting PIP3 into PIP2. 
 
Dysregulation of the PI3K/Akt/mTOR signaling pathway is common in human cancers [2,7]. Gain 
of function mutations of the catalytic as well as the regulatory subunits of PI3K have been identified in a 
variety of tumors [20,21]. Similarly, activating mutations of AKT have been described in cancers [22,23]. 
In addition, since PI3K signals are often activated by receptor tyrosine kinases (RTK), aberrant PI3K 
signaling is also observed in cancers harboring mutations of RTK. Furthermore, as PI3K is also a 
downstream effector of the small GTPase Ras, increased PI3K activity is also common in cancer with 
Ras mutations [24]. Finally, loss of function of the tumor suppressor phosphatase and tensin homolog 
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deleted on chromosome 10 (PTEN) is frequently reported in cancers [25]. As physiologically, PTEN 
terminates PI3K signals by dephosphorylating PIP3 into phosphatidylinositol 4,5-bisphosphate (PIP2), 
the inactivation of PTEN observed in tumors results in the activation of PI3K/Akt signaling. 
Since mTOR plays a central role in cell growth and proliferation and since it is frequently over 
activated in tumor cells, mTOR represents an ideal target in cancer therapy. Indeed, several clinical 
trials have already been performed and have evaluated the anticancer potential of mTOR inhibitors. 
3. mTOR and Cancer; What We Have Learned From Clinical Trials 
The effect of mTOR inhibition in clinical trials has been extensively studied using rapalogs that 
specifically inhibit mTORC1. Rapalogs interact with the immunophilin FK506-binding protein 
(FKBP12) and together bind the FKBP12-rapamycin binding domain of mTOR, resulting in the 
inhibition of mTORC1 [26]. Notably, recent studies have shown that only certain functions of 
mTORC1 are targeted by rapalogs [27]. In contrast to mTORC1, mTORC2 is insensitive to short-term 
exposure of rapalogs. However, depending on the cell type, prolonged exposure to rapalogs also 
inhibits mTORC2 [28]. 
Preclinical studies have shown that rapalogs exert their anti-cancer effects in part by inhibiting cell 
proliferation. Rapalogs reduce the synthesis of proteins involved in cell cycle progression resulting in a 
G1 cell cycle arrest [7]. At the molecular level, inhibition of mTORC1 induces the dephosphorylation 
of 4E-BP1which in turn binds eIF4E, preventing it from interacting with the cap structure of the 5’ 
untranslated regions of mRNA. Consequently, cap-dependent translation initiation is impaired, 
particularly affecting mRNAs with highly structured 5’untranslated regions, like those encoding for 
cyclin D1, c-myc or VEGF [29]. Thus, 4E-BP1 appears to be an important target of mTOR that 
influences cancer growth. Indeed, rhabdomyosarcoma cells harboring very low level of 4E-BP1 are 
resistant to the growth inhibitory effects of rapamycin [30]. In addition to their effects on 4E-BP1, 
rapalogs also inhibit the G1-S cell cycle progression by blocking the phosphorylation of the 
retinoblastoma protein (pRb). On one hand, rapalogs decrease the expression of cyclin D1, therefore 
reducing the level of active cyclin-dependent kinase (cdk)/cyclin D1 complexes which regulate pRb 
phosphorylation. On the other hand, rapalogs also up-regulate p27 expression which negatively affects 
cdk [31,32]. 
Following encouraging pre-clinical studies, the anticancer efficacy of rapalogs has been less 
successful than expected in the clinic [33]. To date, rapalogs have been approved for the treatment of 
advanced renal cell carcinoma. Patients with poor-prognosis renal cell carcinoma receiving 
temsirolimus had a significantly longer overall survival and progression-free survival compared to 
patients treated with interferon [34]. Similarly, in renal cell carcinoma patients who failed prior 
therapy, everolimus significantly extended the progression free survival [35]. In addition to advanced 
renal cell carcinoma, rapalogs showed also efficacy in mantle cell lymphoma. Temsirolimus 
significantly increased progression-free survival compared to the investigator’s choice therapy in 
patients with refractory mantle cell lymphoma [36]. Finally, more recently, everolimus also prolonged 
progression-free survival among patients with progressive advanced pancreatic neuroendocrine  
tumors [37]. Interestingly, the use of mTORC1 inhibitors in these types of cancer relies also on a 
biological rationale. Indeed, renal cell carcinoma is a highly vascularized tumor due to the excessive 
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production of vascular endothelial growth factor (VEGF). At the molecular level, the production of 
VEGF is a consequence of the accumulation of the hypoxia-inducible factor alpha (HIF-. Since 
mTORC1 regulates HIF- expression, the antitumor effects of rapalogs in renal cell carcinoma appear 
to be due to the inhibition of vessel formation in these tumors [38]. Similarly, the genetic hallmark of 
mantle cell lymphoma is the chromosomal translocation t(11;14) resulting in the accumulation of 
cyclin D1 and cell cycle progression [39]. As translation of cyclin D1 mRNA depends on mTORC1 
activity, mTORC1 inhibition reduces cyclin D1 accumulation. Finally, PTEN is frequently down 
regulated in pancreatic endocrine tumors resulting in the activation of the PI3K/Akt/mTOR pathway [40]. 
In addition, rapalogs are being evaluated in phase I-III clinical trials for several other cancers 
including ovarian, endometrial, glioblastoma, bladder, prostate cancer as well as hematological 
malignancies [41]. Given the high prevalence of PI3K/Akt/mTOR activation resulting from loss of 
PTEN expression, a strong rationale exists to use mTOR inhibitors in prostate cancer [42,43]. Several 
clinical trials are ongoing but preliminary analysis have shown that rapamycin is well tolerated in 
prostate cancer patients and decreases the level of mTORC1 activity in the tumor [44,45]. However, 
there was no change in Ki-67 or cleaved caspase-3 staining, (respectively markers of cell proliferation 
and cell death) in prostate tumor cells of patients treated with rapamycin for 14 days [45]. In addition, in 
another pilot study, rapamycin also achieved limited clinical responses in patients with hormone-refractory 
prostate cancer [46]. Responses were observed in 2 to 12 patients and stable disease was noted in 4 of  
12 patients. These results suggest that although mTOR represents a promising target in prostate cancer 
patients, future studies are needed to define which patients will likely respond to rapamycin. 
mTOR signaling pathway is also deregulated in several hematological malignancies including acute 
and chronic myeloid leukemia and multiple myeloma [47,48]. Following encouraging pre-clinical 
results, rapalogs were tested in patients with relapsed/refractory acute myeloid leukemia. In a small 
study, nine patients received rapamycin for 28 days. A 50% reduction of blood or bone marrow blasts 
was reported in 4 patients [49]. Partial or total responses were also reported in 22% of patients 
receiving rapamycin in combination with an etoposide-based chemotherapy [50]. In chronic myeloid 
leukemia, the fusion protein BCR-ABL is the trigger of the disease and is specifically targeted by 
tyrosine kinase inhibitors such as imatinib. Of note, BCR-ABL-mediated mTOR activation is involved 
in the progression of the disease and studies have shown that blocking mTOR might be promising in 
patients that are resistant to imatinib [51]. In multiple myeloma, emerging evidence demonstrates that 
mTOR is an important mediator of cell proliferation and survival [52]. In fact, rapalogs are being 
evaluated clinically and a phase II trial has reported an overall response rate of 38% in patients with 
relapsed multiple myeloma [53]. Finally, the effects of rapalogs are also being investigated in acute 
lymphoid leukemia and in chronic lymphocytic leukemia. In particular, in chronic lymphocytic 
leukemia, clinical responses were observed in 4 out of 22 patients [54] and clinical responses were also 
reported in another phase II trial that was stopped due to toxicities of rapamycin [55]. 
Finally, therapies that indirectly inhibit mTOR have also shown clinical promises in cancer therapy 
and further underline the importance of mTOR in cancer biology. For example, the biguanide 
metformin used to treat type 2 diabetes has emerged as an anticancer agent. Indeed, several 
retrospective epidemiological studies have demonstrated a reduced cancer risk in diabetic patients 
treated with metformin [56-58]. In addition, prospective clinical trials have also been initiated in  
non-diabetic patients to evaluate the anticancer efficacy of metformin. Preliminary analysis have 
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shown that metformin possesses favorable effects on tumor cell proliferation and apoptosis [59]. 
Several mechanisms have been proposed to explain the anticancer activity of metformin. Among those, 
metformin directly reduces the growth of cancer cells in vitro [56]. At the molecular level, metformin 
induces the activation of AMPK which results in the inactivation of mTORC1. In addition, metformin 
also increases the expression of REDD1 which inhibits mTORC1 [60]. Thus, these studies suggest that 
the anticancer efficacy of metformin relies in part on its ability to inhibit mTORC1 [61]. Future studies 
will further explore the effects of metformin in cancer patients and further elucidate the role of 
metformin induced-mTORC1 inhibition in these effects. 
In summary, despite numerous clinical trials, few cancers have responded to rapalogs. Furthermore, 
the benefits of rapalogs were limited in these cancers. These studies also underline the importance of 
identifying biomarkers capable of predicting patients that are likely to respond to rapalogs. Although 
preclinical studies have suggested that mutations in the PI3K/Akt pathway, such as loss of PTEN 
expression, render tumors more sensitive to rapalogs, no reliable biomarker has been identified in 
patients [62]. The use of new technologies such as gene expression or phosphoproteomic profiling will 
probably help identify new biomarkers [63]. Such clinical analysis using high-throughput genomics 
has already been initiated in the context of renal cell carcinoma treated with everolimus [64]. Finally, 
in addition to predictive biomarker, pharmacodynamic biomarkers are also needed to assess the 
efficacy of rapalogs as well as to identify the active doses. Phosphorylation of downstream effectors of 
mTORC1 has been proposed as pharmacodynamic markers and will need to be confirmed in larger 
studies [65]. 
4. mTOR and Cancer; What We Have Learned from the Use of Rapamycin in Transplant 
Patients 
The development of cancer is a major concern in transplant patients following immunosuppression 
with an overall risk of cancer increased by three to fivefold [66]. Skin cancers, Kaposi’s sarcoma and 
lymphoproliferative disease are the most predominant post transplant malignancies. Transplant 
recipients are at increased risk of cancer as immunosuppression impairs immune response against 
tumor cells. In addition, some of the immunosupressive drugs also promote tumor growth by 
increasing angiogenesis and cancer cell aggressiveness [67,68]. Therefore, in this context, a 
therapeutical approach to prevent graft rejections and tumor development is to use rapalogs that have 
both immunosuppressive and anticancer effects [69]. Very few prospective studies have analyzed the 
effect of rapalogs on cancer development in transplanted patients as a primary endpoint. Nevertheless, 
a single center prospective randomized trial has shown that, in renal transplant recipients that had 
developed premalignant skin lesions, conversion of their immunosuppression to rapamycin stopped the 
progression of the lesion or induced its regression. In addition, rapamycin also reduced the incidence 
of nonmelanoma skin cancer in these patients [70]. A lower incidence of malignancy was also reported 
in a larger cohort of kidney recipients following the conversion of the immunosuppression to 
rapamycin [71]. Finally, case studies have also shown that rapamycin reduce the incidence of cancers 
in transplanted patients [72]. In addition, the efficacy of rapamycin was also reported on the regression 
of established tumors. Indeed, several case studies have reported that rapamycin is effective in treating 
Kaposi’s sarcoma in transplanted patients [73,74]. As Kaposi’s sarcoma is a highly vascularized 
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tumor, rapamycin might be particularly efficient due to its anti-angiogenic property [4,75]. 
Interestingly, other mechanisms have also been proposed to explain the efficacy of rapamycin in these 
cancers such as reduced immunosuppression following conversion to rapamycin. However, more 
importantly, it was reported that, in two liver recipients that had developed Kaposi’s sarcoma, 
conversion to rapamycin was associated with the recovery of CD4 and CD8 memory T cells against 
human herpes virus 8 that is responsible for the disease [76]. Furthermore, no recovery of CD4 
memory T cells was observed in a kidney recipient for whom rapamycin failed to induce tumor 
regression. Transplanted patients treated with rapamycin had also better outcome with regard to 
cytomegalovirus infection compared to patients with standard immunosuppression, suggesting that 
rapamycin might enhance the immune response [77]. These observations confirm recent findings that 
suggest that rapamycin have dichotomous effects in immunobiology. Indeed, emerging data support 
immunostimulatory properties of rapalogs. Rapamycin induces immunostimulatory effects on CD8
+
 
memory T cell response after pathogen infection [78,79] and also promotes CD8
+
 T cell-mediated 
antitumor activity [80]. In contrast, rapalogs have been used for a long time as immunosuppressive 
agents as they inhibit the proliferation of T cell following antigen stimulation [81]. In addition, 
rapamycin also increases the generation of T regulatory cells, a subset of T cells that promotes 
tolerance to an antigen [82]. Furthermore, the immunodepressive functions of mTORC1 inhibitors 
were also supported by their inhibitory effects on dendritic cells [83]. Therefore, it appears that 
rapalogs can exert both immunosuppressive and immunostimulatory effects. Future studies will help 
clarify the conditions and parameters regulating these aspects of mTORC1 inhibitors. Clearly, 
avoiding the immunosuppressive while increasing the immunostimulatory properties of mTORC1 
inhibitors will influence the anticancer efficacy of mTORC1 inhibitors. 
Finally, patients treated with rapalogs are also at an increased risk of developing interstitial 
pneumonitis and other inflammatory-related complications [84]. Histologically, this pneumonitis is 
characterized by neutrophils and CD4 T helper cells infiltrates in the absence of infection. Consistent 
with this observation, proinflammatory properties of mTORC1 inhibitors have also been described in 
various experimental models [85]. Emerging data has shown that the PI3K/Akt/mTOR pathway plays 
an important role in regulating inflammatory mediators in myeloid cells by limiting the inflammatory 
responses in dendritic cells and macrophages [85]. Moreover, mTOR reduces tissue infiltration by 
leukocytes by diminishing the expression of the adhesion molecule ICAM-1 by the endothelium [86]. 
Taken together, these observations show that mTOR inhibition promotes inflammation. As inflammatory 
cells play a pivotal role in the tumor microenvironment, future studies will define the effect of mTOR 
inhibitors on inflammatory cells present in the tumor microenvironment. 
5. mTOR and Cancer; What We Have Learned from Basic Research 
In parallel to the clinical trials, progresses have been made in mTOR biology. In addition to the 
identification of two distinct complexes, mTORC1 and mTORC2, experimental studies have also 
revealed a complex network between mTOR and other signaling pathways [87]. It thus became clear 
that the inhibition of mTORC1 induces the activation of other prosurvival signals that counteract their 
anticancer efficacy (Figure 3). In fact, rapalogs block a negative feedback loop whereby activation of 
mTORC1 and its downstream effector S6K1 reduces PI3K/Akt activity [87]. At the molecular level, 
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down regulation of insulin receptor substrate 1 (IRS-1) by S6K1 as well as down regulation of  
platelet-derived growth factor have been involved in this negative feedback loop [88,89]. 
Figure 3. mTORC1 inhibition activates proliferative and prosurvival pathways. Activation 
of mTORC1 leads to the inhibition of PI3K through a negative feedback loop that involves 
S6K1. The negative feedback loop is blocked following mTORC1 inhibition by rapalogs. 
This leads to the activation of PI3K/Akt and Raf/Mek/Erk proliferative and prosurvival 
signals that counteract the anticancer efficacy of rapalogs. 
 
Interestingly, rapalogs-mediated Akt activation has also been described in patients treated with the 
rapalog RAD001. Biopsies of liver metastases or skin lesions of patients with colon or breast 
carcinoma were analyzed before and after 4 weeks of treatment with RAD001. Immunhistochemistry 
studies revealed that the levels of Akt phosphorylation were higher following RAD001 treatment [90]. 
Similarly, Akt phosphorylation was analyzed in various tumors of patients receiving RAD001 [91]. 
Akt phosphorylation was increased in 50% of the treated tumors. Increased Akt phosphorylation was 
also noted in skin biopsies [91]. The effect of rapamycin on Akt phosphorylation was also assessed in 
patients with recurrent glioblastoma which lacked PTEN expression [92]. Rapamycin led to increased 
Akt phosphorylation in tumors in seven of fourteen patients. Akt activation was also associated with 
shorter time-to-progression in these patients suggesting that combining rapalogs with inhibitors that 
block Akt activity may be useful in patients. This study also illustrates the difficulties of predicting the 
effect of rapalogs on Akt as only 50% of the patients had increased Akt phosphorylation in the tumor 
following rapamycin treatment although all patients suffered from glioblastoma.  
In addition to the feedback loop connecting mTORC1/S6K1 to PI3K/Akt, recent studies have also 
shown that blocking mTORC1/S6K1 with rapalogs activates the Raf/Mek/Erk signaling pathway in a 
PI3K dependent manner [93]. Treatment of cancer cell lines with rapamycin increased Mek/Erk activity 
and pharmacological blockade of Mek increased the growth inhibitory efficacy of rapamycin [93,94]. 
Most importantly, rapalogs-mediated Erk activation was also reported in patients. Immunohistochemical 
analysis of tumor biopsies before and after RAD001 treatment showed that Erk phosphorylation was 
Cancers 2011, 3              
 
 
2487 
increased following treatment [93]. It is also worth noting that rapalogs induced Erk activation is cell 
type dependent. For example, treatment of HCT-116, MCF-7 or DU145 cells with rapamycin did not 
increase Erk phosphorylation [94]. Furthermore, combination therapy using rapamycin and Mek 
inhibitors decreased the growth of prostate cancer cells more effectively than either agent alone, 
although rapamycin did not increase Erk phosphorylation in these cells [95]. This suggests that Mek 
inhibitors would potentiate the anticancer efficacy of rapalogs regardless of whether rapalogs increase 
Erk activity. Therefore, it might be more relevant in identifying tumors that will respond to combined 
mTOR and Mek inhibitions rather than determining the tumors for which mTORC1 inhibition leads to 
Erk activation. Of relevance to cancer therapy, mTOR inhibition also increases Mek/Erk signaling in 
endothelial cells [96]. Targeting mTOR and Mek simultaneously has additive anti-angiogenic effects 
both in vitro and in vivo. Therefore combining mTOR and Mek inhibitors might have synergistic 
effects both on tumor cells and on the tumor vasculature. 
In addition to the activation of PI3K/Akt and Mek/Erk signaling pathways, rapalogs induce other 
signals that might compromise the antitumor effects of rapalogs. For example, mTORC1 inhibition 
leads to the paradoxical phosphorylation of eIF4E in several types of cancer cells [97]. eIF4E regulates 
the initiation translation of mRNA with 5’untranlsated regions including a number of transformation 
related genes and has been identified as a potential oncogene [98]. Notably, rapalogs mediated eIF4E 
phosphorylation was dependent on Mnk (MAP kinase interacting kinase) and the inhibition of Mnk 
increased rapamycin-mediated growth inhibition [97]. Finally, it has also been reported that 
rapamycin-activated JNK signaling pathway in colon cancer cells plus combined JNK and mTOR 
inhibition had additive anti-tumor effects [99]. Future studies will explore the relevance of rapalogs 
mediated eIF4E or JNK activation in a clinical setting. 
6. Enhancing the Anticancer Efficacy of mTORC1 Inhibitors 
As mentioned earlier, rapalogs used as single agents have shown very limited benefits in cancer 
therapy. This might be partly explained by the observation that rapalogs induce the activation of other 
signaling pathways, resulting in proliferative and prosurvival signals that impede the anticancer 
efficacy of rapalogs. Therefore, combining rapalogs with other agents implicated in these feedback 
activations should improve the efficacy of rapalogs in cancer therapy. 
In this context, preventing rapalogs-mediated PI3K/Akt activation has already shown promising 
effects. Since growth factor receptors act upstream of the PI3K/Akt signaling pathway and have been 
involved in mTORC1-mediated PI3K/Akt activation, combining growth factor receptor inhibitors with 
rapalogs is a reasonable strategy. Indeed combining IGF-1R inhibitors with rapalogs exert additive 
antiproliferative effects compare to single treatment in prostate, breast cancer and myeloma  
cells [90,100]. Interestingly, this strategy is already under clinical evaluation [101]. Targeting other growth 
factor receptors such as EGFR with rapalogs also results in enhanced anticancer efficacy [102,103]. 
Another strategy to increase the anticancer efficacy of rapalogs is to combine rapalogs with PI3K 
inhibitors. In fact, PI3K appears to be a central player in the feedback activation mediated by rapalogs. 
As mentioned earlier, mTORC1 inhibition-mediated Akt, Erk and Mnk activation is PI3K dependent. 
Such a strategy has already been tested in experimental models and has shown that LY294002, a PI3K 
inhibitor, enhanced the growth inhibitory effects of rapalogs in lung cancer cells as well as in T-cell 
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leukemia cells [94,104]. While LY294002 cannot be used in the clinic due to its high toxicity, several 
other PI3K inhibitors have been developed and are under clinical evaluation [105]. 
Akt inhibitors have also been developed and tested in association with rapalogs. It was reported that 
the Akt inhibitor perifosine, in combination with nanoparticle bound rapamycin had increased  
anti-tumoral activity compared to either agent alone in multiple myeloma [106]. Furthermore, targeting 
downstream effectors of Akt such as Foxo proteins may also potentiate the anticancer efficacy of 
rapalogs [107]. 
As mentioned earlier, mTORC1 inhibition leads to the activation of Erk and targeting both Erk and 
mTOR signaling pathways has additional antitumoral and anti-angiogenic effects [96,108]. Consistent 
with these findings, combining rapalogs with sorafenib, which blocks Raf an upstream activator of 
Erk, exerted an enhanced anti-tumoral effect compared to rapalogs or sorafenib alone [109,110]. 
Finally, although the above mentioned strategies to improve rapalogs anticancer efficacy rely on a 
biological rationale, it is worth noting that rapalogs efficacy can be enhanced by molecules that have 
no obvious link with mTOR signaling pathway. For example, the anticancer activity of rapalogs is 
improved by vorinostat a histone deacetylase inhibitor [111]. Furthermore, DNA methyltransferase 
inhibitors also potentiate the anticancer efficacy of rapamycin in colon cancer cells [112]. 
In summary, several new therapeutic strategies have improved the anticancer efficacy of rapalogs in 
experimental models. Ongoing clinical trials will reveal their efficacy and tolerability in patients. 
7. Enhancing mTOR Targeted Therapies; ATP-Competitive Inhibitors of mTOR 
The identification that mTOR acts in two distinct complexes, mTORC1 and mTORC2, and that 
mTORC2 is insensitive to rapamycin has led to the rapid development of inhibitors able to block both 
mTORC1 and mTORC2 [113,114]. It was speculated that blocking both complexes would produce 
stronger anticancer effects than rapalogs. Indeed, mTORC2 exerts an emerging role in cancer 
development and has been shown to participate in prostate and colon cancer progression [26,115]. 
Several such inhibitors have been developed and characterized [114]. Acting as ATP-competitive 
inhibitors, they either specifically block mTORC1 and mTORC2 or induce a dual inhibition 
PI3K/mTOR. The anticancer efficacy of these inhibitors has been tested in various experimental tumor 
models [38,116]. Overall, the anticancer and anti-angiogenic efficacies of ATP-competitive inhibitors 
of mTOR are superior to those of rapamycin [116]. 
Indeed, AZD8055, a specific mTOR inhibitor, showed antiproliferative effects in various cancer 
models that were superior to those of rapamycin. Interestingly, cancer cells that did not respond to 
rapamycin were sensitive to AZD8055 [117,118]. Similarly, WYE-132 that blocks both mTORC1 and 
mTORC2 induced a stronger inhibition of cancer cell growth and survival compared to temsirolimus [119]. 
Of note WYE-132 but not temsirolimus also achieved regression of tumors in vivo through the 
induction of tumor cell apoptosis, suggesting that mTOR kinase inhibitors might have cytolytic 
properties [119]. Furthermore, targeting mTORC1 and mTORC2 with the chemical compounds  
OSI-027 or OXA-01 reduces tumor growth more efficiently than rapamycin [120]. The anti-angiogenic 
effects of OSI-027 and OXA-01 were also superior to those of rapamycin. Finally, the inhibition of 
mTORC1 and mTORC2 with PP242 in leukemic cells that express the BCR-ABL oncogene, results in 
a strong anti-leukemic activity that is superior to rapamycin [121]. 
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As mentioned earlier, dual mTOR/PI3K inhibitors have also been developed. These drugs target the 
ATP binding sites of both mTOR and PI3K and therefore block mTORC1, mTORC2 as well as PI3K. 
Several dual inhibitors such as NVP-BEZ235 have already been tested and have shown antitumor 
activity in numerous preclinical cancer models [116]. Interestingly, NVP-BEZ235 displayed  
anti-tumor efficacy in cancer models harboring PI3K mutations but not K-Ras mutations underlining 
the importance to define biological markers that will predict the response to these drugs [122,123]. In 
addition, the anti-cancer efficacy of NVP-BEZ235 has also been compared to rapamycin. In renal cell 
carcinoma, NVP-BEZ235 reduced the growth of tumor xenografts more efficiently than rapamycin [124]. 
NVP-BEZ235 also induced tumor cell apoptosis which was not observed with rapamycin.  
NVP-BEZ235 has been tested in pre-clinical models of hematological malignancies. It significantly 
reduces acute myeloid leukemia cell proliferation and survival [125]. In addition, NVP-BEZ235 also 
showed anti-tumoral activity in Waldenstrom macroglobulinemia and T-cell acute lymphoblastic 
leukemia [126,127]. Other dual PI3K/mTOR inhibitors have been evaluated and consistently showed 
the inhibition of tumor growth [116]. 
Of note, ATP-competitive inhibitors of mTOR have also shown efficacy in tumor models of 
genetically engineered mice, which may reflect the pathogenesis of human cancers more closely than 
xenograft models. In a mouse model of lung adenocarcinomas generated by the expression of a 
constitutively active mutant of the catalytic subunit of PI3K, a marked tumor regression was observed 
following treatment with NVP-BEZ235 [128]. Similarly, in a transgenic murine ovarian cancer model 
triggered by the expression of an active K-ras mutant and the loss of PTEN expression, mice treated with 
NVP-BEZ235 survived significantly longer [129]. Finally, AZD8055, a specific mTORC1/mTORC2 
inhibitor reduced the growth of B-cell follicular lymphoma that develops in PTEN-deficient mice [130]. 
At the molecular level, several mechanisms explain the greater anitumoral efficacy of ATP kinase 
inhibitors of mTOR compared to rapalogs. ATP-competitive inhibitors not only inhibit mTORC2 but 
have also a broader inhibitory effect on mTORC1. Indeed, the proliferation of mouse embryo 
fibroblasts is slightly reduced by rapamycin while it is totally blocked by Torin 1 or PP242, two  
ATP-competitive inhibitors of mTOR [131,132]. A similar response is observed in mouse embryo 
fibroblasts lacking mTORC2 activity, showing that the stronger efficacy of mTOR kinase inhibitors 
was a consequence of a more pronounced inhibition of mTORC1 rather than the inhibition of 
mTORC2. Moreover, Torin1 and PP242 inhibited 4E-BP1 phosphorylation and cap-dependent mRNA 
translation, that both depend on mTORC1 activity, more efficiently than rapamycin [131,132]. 
As discussed previously, an important limitation of rapalogs is the removal of a negative feedback 
loop, resulting in the activation of PI3K/Akt signaling pathway which counteract the efficacy of 
rapalogs [87]. Akt requires the phosphorylation of the amino acid residues S473 and T308 to be fully 
activated. While mTORC2 phosphorylates Akt on S473, PDK-1 a downstream effector of PI3K 
regulates T308 phosphorylation. Specific mTOR kinase inhibitors have shown contradictory results on 
Akt phosphorylation. Whereas Ku-0063794 inhibited Akt S473 and T308 phosphorylation at the same 
concentration, AZD8055 required higher doses to block T308 phosphorylation [117,133]. In contrast, 
WYE-125132 inhibited S473 phosphorylation but had no effect on T308 [119]. This might be 
particularly relevant as T308 phosphorylated Akt is still able to activate a subset of downstream 
effectors even in the absence of S473 phosphorylation [134]. Therefore, additional studies are required 
to investigate the effects of specific mTOR kinase inhibitors on Akt activity. In contrast, dual 
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PI3K/mTOR inhibitors consistently inhibited the phosphorylation of Akt on T308 and S473 and thus 
might have a stronger inhibitory effect on Akt than specific mTOR kinase inhibitors. 
Finally, activation of Mek/Erk signaling pathway following exposure of cancer cells to  
ATP-competitive inhibitors of mTOR has also been reported even with dual PI3K/mTOR inhibitors [124]. 
This finding suggests that combining Mek and ATP-competitive inhibitors of mTOR may have 
additive anticancer effects. Consistent with this hypothesis, the anti-angiogenic efficacy of combined 
Mek and ATP-competitive inhibitors of mTOR is superior to either inhibitor alone [96]. A similar 
observation has been reported in a model of Waldenstrom macroglobulinemia [126]. 
In summary, these studies show that ATP-competitive inhibitors of mTOR display a stronger 
antiproliferative effect than rapalogs and also frequently induce cancer cell apoptosis, which is rarely 
observed with rapalogs. Current clinical studies are evaluating their efficacy in cancer patients [41]. 
8. Conclusions 
Clinical trials have shown that the inhibition of mTORC1 by rapalogs has limited benefits in 
oncology when used in monotherapy. However, findings in basic research, that were confirmed in 
patients, have revealed that blocking mTOR induces the activation of proliferative and prosurvial 
signals that limit the anticancer efficacy of mTORC1 inhibitors. New therapeutic strategies that 
associate inhibitors of these proliferative and prosurvival signals in combination with mTORC1 
inhibitors have proven their efficacies in experimental models and are being evaluated in ongoing 
clinical trials. In addition, the anticancer efficacy of ATP-competitive inhibitors of mTOR, that in 
contrast to rapalogs block both mTORC1 and mTORC2, are superior to rapalogs. Their toxicity and 
efficacy are being currently tested in clinical studies. Finally, emerging data show that the role of 
mTOR in cancer biology is not limited to the proliferating cancer cells but involves the tumor 
microenvironment. Particularly, the role of mTOR in innate and adaptive immune cells needs to be 
further explored in the context of cancer. 
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